PRF Technologies (PRFX) Common Equity (2019 - 2025)
PRF Technologies' (PRFX) quarterly Common Equity came in at $9.3 million in Q4 2025, up 409.32% YoY from $1.8 million in Q4 2024, and up 10.03% on a QoQ basis from $8.4 million in Q2 2025.
PRF Technologies (PRFX) Common Equity (2019 - 2025) Analysis & Trends
PRF Technologies (PRFX) has 7 years of Common Equity data on file, last reported at $9.3 million in Q4 2025.
- Quarterly Common Equity rose 409.32% year-over-year to $9.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.3 million (up 409.32% YoY) and the FY2025 annual result came in at $9.3 million, up 409.32% from the prior year.
- Common Equity grew to $9.3 million in Q4 2025, from $8.4 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $20.4 million in Q1 2021 to a low of -$2.0 million in Q2 2024.
- A 5-year average of $10.8 million and a median of $9.3 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 129.27% — and 2025, when it surged 513.67%.
- Tracing PRFX's Common Equity over 5 years: stood at $18.1 million in 2021, then slumped by 39.05% to $11.0 million in 2022, then sank by 34.32% to $7.2 million in 2023, then sank by 74.8% to $1.8 million in 2024, then jumped by 409.32% to $9.3 million in 2025.
- The last three Common Equity figures came in at $9.3 million (Q4 2025), $8.4 million (Q2 2025), and $1.8 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | PRF Technologies | 654,452.72 | -3.49 Mn | - | 9.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 9.29 Mn |
| Jun 30, 2025 | 8.44 Mn |
| Dec 31, 2024 | 1.82 Mn |
| Jun 30, 2024 | -2.04 Mn |
| Mar 31, 2024 | 1.85 Mn |
| Dec 31, 2023 | 7.24 Mn |
| Sep 30, 2023 | 8.64 Mn |
| Jun 30, 2023 | 6.97 Mn |
| Mar 31, 2023 | 8.89 Mn |
| Dec 31, 2022 | 11.02 Mn |
| Sep 30, 2022 | 13.42 Mn |
| Jun 30, 2022 | 15.20 Mn |
| Mar 31, 2022 | 16.70 Mn |
| Dec 31, 2021 | 18.08 Mn |
| Sep 30, 2021 | 19.48 Mn |
| Jun 30, 2021 | 19.01 Mn |
| Mar 31, 2021 | 20.40 Mn |
| Dec 31, 2020 | 16.62 Mn |
| Jun 30, 2020 | -14.16 Mn |
| Dec 31, 2019 | -12.24 Mn |